Back to search results

Study of Whole Breast Irradiation and Boost for Early-Stage Breast Cancer

This study is looking at a type of radiation therapy called Whole Breast Irradiation (WBI) with a Simultaneous Integrated Boost (SIB) for women with early-stage breast cancer. The goal is to see how well this ultra-short treatment works for cosmetic results, patient experiences, and side effects. You might be able to join if you are a woman aged 18 or older with early-stage invasive breast cancer or DCIS (Ductal Carcinoma In Situ) who has had breast-conserving surgery. The main way success will be measured is by looking at cosmetic outcomes up to two years after treatment. This study plans to enroll 50 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
You would have 5 treatment visits and 7 study visits over approximately 5.5 years. These visits include assessments before treatment and at 6 weeks, 12, 24, 36, 48, and 60 months after treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 60 months (5 years) after treatment to assess various outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06295744

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

Active, Not Recruiting
NAAges 18+InterventionalTreatment
University of Wisconsin, Madison
~50 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:Radiation Therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Harvard Breast Cosmesis Scale Score
Measured over up to 2 years post-treatment (treatment ends up to 5 weeks on study)

Conditions

Early-stage Breast Cancer

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Jessica Schuster, MD · PRINCIPAL_INVESTIGATOR · UW Carbone Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and the willingness to sign a written informed consent document
Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS
Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx
Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques
Treatment plan includes breast tumor bed boost
Willingness to comply with all study procedures and be available for the duration of the study

Exclusion

Mastectomy of ipsilateral breast
Lack of histologic diagnosis
Histologic involvement of the axillary or regional nodes or metastatic disease
Accelerated partial breast irradiation treatment plan
Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin
Previous history of chest radiation therapy
Previous history of ipsilateral breast cancer
Concurrent cytotoxic chemotherapy
Active connective tissue disease including scleroderma
Inability or unwillingness to return for required follow up visit

What this trial measures

  • Harvard Breast Cosmesis Scale Scoreup to 2 years post-treatment (treatment ends up to 5 weeks on study)

    4-point scale where 1 is excellent, 2 is good, 3 is fair, and 4 is poor.